-

Bruker Corporation to Present at Upcoming Investor Conferences

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences:

2024 Wells Fargo Healthcare Conference in Boston, MA
Wednesday, September 4, 2024, at 10:15 a.m. Eastern Time

Morgan Stanley 22nd Annual Global Healthcare Conference in New York City
Friday, September 6, 2024, at 10:00 a.m. Eastern Time

Live audiovisual webcasts of the presentations will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. Replays of the presentations will be posted in the “Events & Presentations” section of the Bruker Corporation Investor Relations website after the events and will be available for 90 days following the presentations.

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Contacts

Joe Kostka
Associate Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Versions
$Cashtags
Hashtags

Contacts

Joe Kostka
Associate Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Social Media Profiles
More News From Bruker Corporation

Bruker Reports Third Quarter 2026 Financial Results

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three and nine months ended September 30, 2026. Frank H. Laukien, Bruker’s President and CEO, commented: “Bruker drives significant advances in post-genomic drug discovery and disease biology research, from proteoforms to glycobiology, and from functional protein interactions to spatial biology. These deeper insights into molecular, cell and tissue biology are foundational for successf...

Bruker Announces Date and Time of Third Quarter 2026 Earnings Release and Webcast

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced it will report third quarter 2026 financial results before market opening on Wednesday, November 4, 2026. The Company will host a conference call and webcast at 8:30 a.m. Eastern Daylight Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q3 2026 Earnings Webcast” hyperlink in the “Events & Presentations” section. A...

Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution

BERLIN--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced a seminal bioRxiv preprint, describing a draft atlas of the human plasma proteome at isoform, or proteoform, resolution. The study was conducted by principal investigator Markus Ralser at Charité – Universitätsmedizin Berlin and collaborators. The preprint “A draft atlas of the human plasma proteome at isoform resolution” was posted on September 28, 2026 at https://doi.org/10.64898/2026.09.26.754256. By combining intact protei...
Back to Newsroom